Cancer - APEC1621A: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions
Condition or Therapy:
What is the goal of this study?
The goal of this study is to answer the following question: what is the complete and partial response rate in pediatric patients who have advanced solid tumors, non-Hodgkin lymphomas, or histiocytic disorders with NTRK fusions. We will also estimate the remission rates with this treatment and look at how eligible children tolerate the protocol treatment.
Who can join the study?
This study may be a good fit for children and young adults who:
- Are ≥12 months and ≤21 years of age
- Have a measurable disease
- Have a NTRK gene fusion mutation
What will happen if my child takes part in this study?
If you choose to participate in this study:
- You will take the study drug daily and keep track in a diary
Who can I contact for more information?
Please email Angela Bleeker or call the study team at (206) 987-2106